Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis.
A prospective, nonrandomized study was performed to evaluate the role of endotoxin and tumor necrosis factor (TNF) in dogs with parvoviral enteritis. Seventeen dogs with naturally occurring parvoviral enteritis were enrolled in the study. Plasma samples were obtained for quantification of endotoxin and TNF on presentation and at 3 and 6 hours after therapy with either fluids prior to antibiotics, or fluids concurrently with antibiotics. All dogs received standard supportive therapy. Fourteen of 17 dogs had endotoxin in their plasma during the study period; 7 of 17 dogs had measurable TNF. No endotoxin or TNF was detectable in plasma from normal puppies. An increase in TNF activity was predictive of mortality (P = .041). There was a trend for increasing endotoxin activity to predict mortality (P = .0769). Animals that received antibiotics with fluids were significantly older than those that received fluids prior to antibiotics, and there was a trend for animals that received antibiotics with fluids to have a decrease in endotoxin activity after treatment (P = .054). Endotoxin and activation of the cytokine cascade are integral to the pathophysiology of parvoviral enteritis. Measures to limit endotoxemia and the systemic inflammatory response may improve survival.
Otto
C M
CM
Emergency Service, University of Pennsylvania, School of Veterinary Medicine, Philadelphia 19104, USA.
Drobatz
K J
KJ
Soter
C
C
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D002440:Cefoxitin / Q000627:therapeutic use; D002513:Cephamycins / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D004285:Dogs; D019446:Endotoxemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D004751:Enteritis / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D010322:Parvoviridae Infections / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D017992:Parvovirus / Q000302:isolation & purification*; D010406:Penicillins / Q000627:therapeutic use; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D002513:Cephamycins; D010406:Penicillins; D014409:Tumor Necrosis Factor-alpha; D002440:Cefoxitin; D000667:Ampicillin